Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation. - Wikidata - awgldk - TriplyDB

Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation.

Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation.

http://www.wikidata.org/entity/Q34765308

about

Dose-adjusted EPOCH-rituximab combined with fludarabine provides an effective bridge to reduced-intensity allogeneic hematopoietic stem-cell transplantation in patients with lymphoid malignancies.Complete donor T-cell engraftment 30 days after allogeneic transplantation predicts molecular remission in high-risk chronic lymphocytic leukaemia.Early donor chimerism levels predict relapse and survival after allogeneic stem cell transplantation with reduced-intensity conditioning.Combination of fludarabine, amsacrine, and cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia.Minimal residual disease following allogeneic hematopoietic stem cell transplantation.Quantitative analysis of chimerism after allogeneic stem cell transplantation by PCR amplification of microsatellite markers and capillary electrophoresis with fluorescence detection: the Vienna experience.Immunotherapy of cancer by active vaccination: does allogeneic bone marrow transplantation after non-myeloablative conditioning provide a new option?Cellular intrinsic mechanism affecting the outcome of AML treated with Ara-C in a syngeneic mouse model.CD34 + cell dose and outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation.Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes.Reduced-intensity allogeneic hematopoietic stem cell transplantation for acute leukemias: 'what is the best recipe?'.Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning.Treatment options for the management of acute leukaemia relapsing following an allogeneic transplant.The allogeneic graft-versus-cancer effect.Allogeneic transplantation in the UK: an aggregation of marginal gains?Prognostic impact of immune status and hematopoietic recovery before and after fludarabine, IV busulfan, and antithymocyte globulins (FB2 regimen) reduced-intensity conditioning regimen (RIC) allogeneic stem cell transplantation (allo-SCT).Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence.Adoptive therapy with donor lymphocyte infusion after allogenic hematopoietic SCT in pediatric patients.Chronic but not acute graft-versus-host disease improves outcome in multiple myeloma patients after non-myeloablative allogeneic transplantation.Analysis of donor-type chimerism in lineage-specific cell populations after allogeneic myeloablative and non-myeloablative stem cell transplantation.Increasing hematopoietic microchimerism is a reliable indicator of incipient AML relapse.Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia.Fludarabine phosphate and melphalan: a reduced intensity conditioning regimen suitable for allogeneic transplantation that maintains the graft versus malignancy effect.Assessing hematopoietic chimerism after allogeneic stem cell transplantation by multiplexed SNP genotyping using microarrays and quantitative analysis of SNP alleles.Long-term systemic lupus erythematosus disease control after allogeneic bone marrow transplantation.Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial.Lineage-specific chimaerism after stem cell transplantation in children following reduced intensity conditioning: potential predictive value of NK cell chimaerism for late graft rejection.Chimerism status is correlated to acute graft-versus-host disease after allogeneic stem cell transplantation.Platelet chimerism by polymerase chain reaction (PCR) utilizing variable number of tandem repeats (VNTR) in allogeneic stem cell transplant in children: a new novel approach to full chimerism analysis.

P2860

Q33399543-397CF1CC-5938-4C0C-B070-3EE2D592ABEB Q34109670-C57C449F-60A9-48A6-AAED-5FDA61846A68 Q34325183-C3DE4386-9916-4A71-A949-8F25263B251C Q34348102-4F215ED8-01D4-4577-ACCC-D5166359CDDE Q34667390-731B2A6C-CEC3-4614-AA95-CB3F85816022 Q35046116-3BB26253-EFD8-450B-AF28-862EC61FE661 Q35142329-A3448ABF-464F-4567-8738-5D9C71405271 Q35331086-4CC66EC5-0D89-4AB3-BA18-96A8F71B6F59 Q35994928-B6216CFE-5659-4F55-83A1-2F751D7054C6 Q36157233-E21B9765-342D-44E9-B3A6-635184B37D10 Q36182976-39F52C73-13C5-43F7-B3AC-39081815DC1B Q36548358-8A8C4A33-0EE7-4717-9AAA-D181F1CE39A2 Q36977560-9E116B6B-08A5-4E81-B98C-EBE9C930695D Q37593125-85135A97-6A11-49DB-9B05-92E8B004F04D Q38124363-5DDAA9A8-758F-4E49-AD55-98C306AE8B6F Q39488956-8E1EAFDF-90B2-4E43-8969-D79E4B02BB23 Q43263268-A4AB1FB2-1491-4428-AEC5-1F91C0EE2C97 Q44208467-B64D93FB-ACF3-4BD2-8E8E-35D7D4F117B6 Q44386867-06AC674A-2E41-4C05-95FE-7ED731D7C728 Q45230503-E8F1DDE8-9CB3-4417-8E73-ADB9228A4370 Q45862572-A1031528-6A95-4AB4-A28E-EFDE761F5E9C Q46668662-7C87471C-A851-4806-9F1C-896C569E5F0B Q46910464-E4525AAC-CA9D-4507-A66A-337A9FEDDE2D Q47324668-7AC7072D-D843-4478-B6C2-1900BB882DA3 Q47962680-0838ACD8-B4EF-4237-8390-4927F4D38EE4 Q50069823-A61438D9-CA54-4B49-A638-93474A43C857 Q50767165-84499D18-6D08-4BC9-8BA6-62E8DC13720A Q54225110-2AAF6BE5-A845-4C1A-980B-C05E66460278 Q54751487-AAA8F576-F620-46F6-8BF3-2162F51FB376

P2860

Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation.

http://www.wikidata.org/entity/Q34765308

description

2002 nî lūn-bûn

@nan

2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Chimerism and minimal residual ...... C) allogeneic transplantation.

@ast

Chimerism and minimal residual ...... C) allogeneic transplantation.

@en

Chimerism and minimal residual disease monitoring after reduced intensity conditioning

@nl

type

label

Chimerism and minimal residual ...... C) allogeneic transplantation.

@ast

Chimerism and minimal residual ...... C) allogeneic transplantation.

@en

Chimerism and minimal residual disease monitoring after reduced intensity conditioning

@nl

prefLabel

Chimerism and minimal residual ...... C) allogeneic transplantation.

@ast

Chimerism and minimal residual ...... C) allogeneic transplantation.

@en

Chimerism and minimal residual disease monitoring after reduced intensity conditioning

@nl

P1433

Q34765308-6010855D-34BC-44CB-B6B3-FE29858B3309

P1476

Q34765308-F5F1C0A5-E915-4FE0-9BDA-0278953751B9

P2093

Q34765308-18F2AD4F-647E-4022-956D-70D9F31C4A88

Q34765308-26BFBD6E-CF87-4A50-8213-1761A24D3C90

Q34765308-2AF3584E-1169-4334-9D0C-2454A24EF208

Q34765308-3FF3D24B-996B-445B-927F-B47699938A51

Q34765308-7AA994F6-0C64-4B03-AA31-6F4B47ECE38F

Q34765308-8D3BF69E-778F-4A8B-82A1-7FF9F982B4E3

Q34765308-90A66400-658B-4EA7-A1D2-1D1E4B640788

Q34765308-926FC9B4-7C19-46C3-A40C-9E6EBA978A11

Q34765308-D8769E6F-DA73-48DD-8449-7C9ABB9E3E60

Q34765308-E5D98D40-0C09-45E3-8716-FA71D9EF1D0B

P2888

Q34765308-F050718C-63B1-4AB0-B9D5-D42310004177

P304

Q34765308-CEE268C8-0A54-4E16-A634-0BC0A455DF6D

P31

Q34765308-234693B8-0EFD-41BF-911D-DCCD79C27DEC

P356

Q34765308-A8871364-DAD4-497E-970E-6B6C6FEA4181

P433

Q34765308-C1C4070F-4149-47F8-A316-A247B4BBFAC7

P478

Q34765308-0869DA4A-A3E9-45FF-9A82-3161A9C3863F

P577

Q34765308-9DD4C041-F0D1-4FAB-BA25-265C7E0387F9

P5875

Q34765308-C5E870CB-3F8E-4699-839C-48565A91D7C4

P6179

Q34765308-538742DD-3153-46C0-AE00-0F67BE4B22D2

P698

Q34765308-884CF8E2-33B7-4D99-87C3-4476F156E33F

P356

P1433

P1476

Chimerism and minimal residual ...... C) allogeneic transplantation.

@en

P2093

Caballero D

http://www.w3.org/2001/XMLSchema#string

Cañizo C

http://www.w3.org/2001/XMLSchema#string

Diez-Campelo M

http://www.w3.org/2001/XMLSchema#string

Gonzalez M

http://www.w3.org/2001/XMLSchema#string

Lopez-Pérez R

http://www.w3.org/2001/XMLSchema#string

Mateos G

http://www.w3.org/2001/XMLSchema#string

Mateos MV

http://www.w3.org/2001/XMLSchema#string

Pérez-Simón JA

http://www.w3.org/2001/XMLSchema#string

San Miguel JF

http://www.w3.org/2001/XMLSchema#string

Vazquez L

http://www.w3.org/2001/XMLSchema#string

P2888

P304

1423-1431

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.LEU.2402550

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2002-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11236289

http://www.w3.org/2001/XMLSchema#string

P6179

1039612343

http://www.w3.org/2001/XMLSchema#string

P698

12145680

http://www.w3.org/2001/XMLSchema#string